Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial
Arthritis & Rheumatology · 2026
DOI: 10.1002/art.43428 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Hermine I Brunner und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Patient Reported Outcome Measures, Arthritis, Juvenile. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Objective
Juvenile idiopathic arthritis (JIA) is associated with impaired overall health‐related quality of life (HRQoL). We evaluated the impact of tofacitinib on patient‐reported outcomes (PROs) in patients with JIA.
Methods
This was a post hoc analysis of a phase 3, randomized, double‐blind, placebo‐controlled withdrawal trial (NCT02592434) in patients with JIA. In the open‐label phase (part 1; weeks 0–18), patients received body weight–based doses of tofacitinib. During the double‐blind phase (part 2; weeks 18–44), responders (per JIA‐American College of Rheumatology 30 response criteria) were randomized 1:1 to continue tofacitinib or switch to placebo for up to 26 weeks. Assessed PROs included the validated parent and/or legal guardian versions of the Childhood Health Assessment Questionnaire for evaluation of disability, arthritis pain, overall well‐being, and the Child Health Questionnaire (CHQ).
Results
Overall, 225 patients were enrolled and received open‐label tofacitinib in part 1, and 173 patients were randomized in part 2. During part 1, least‐squares (LS) mean (SE) disability, arthritis pain, and overall well‐being scores numerically improved from mean 1.04 (SE 0.05), mean 5.53 (SE 0.20), and mean 5.07 (SE 0.20) at baseline to mean 0.57 (SE 0.05), mean 2.46 (SE 0.18), and mean 2.47 (SE 0.18) at week 18, respectively. LS mean (SE) CHQ physical summary and psychological summary scores numerically improved from mean 29.51 (SE 1.15) and mean 47.24 (SE 0.85) at baseline to mean 42.70 (SE 0.98) and mean 51.53 (SE 0.80) at week 18, respectively. Improvements were generally maintained to week 44 in part 2.
Conclusion
Tofacitinib improved a range of PROs in patients with JIA, suggesting potential HRQoL benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
- National Medical Research Center for Children's Health Federal State Autonomous Institution of the Russian Federation Ministry of Health and I. M. Sechenov First Moscow State Medical University (Sechenovskiy University)…
- Hospital Pequeno Principe, Curitiba, Brazil.
- Dell Children's Medical Center of Central Texas, Austin.
- The Sydney Children's Hospital Network, Westmead, New South Wales, Australia.
- Division of Pediatric Rheumatology, University of Utah, Salt Lake City.
ORCID-Profile: Hermine I Brunner, Peter Chiraseveenuprapund, Seza Ozen, Daniel J Lovell
Förderung
- Pfizer
Zitieren
APA
Brunner, H. I., Alexeeva, E., Bandeira, M., Carrasco, R., Chaitow, J., Chiraseveenuprapund, P., Ting, T. V., Erguven, M., Gottlieb, B., Oliveira, S. K., Patel, P. N., Ozen, S., Saad Magalhaes, C., Penadés, I. C., Gruben, D., Germino, R., Posner, H. B., Stockert, L., Martini, A., …, & Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG) (2026). Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial. Arthritis & Rheumatology. https://doi.org/10.1002/art.43428
Vancouver
Brunner HI, Alexeeva E, Bandeira M, Carrasco R, Chaitow J, Chiraseveenuprapund P, et al. Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial. Arthritis & Rheumatology. 2026. doi:10.1002/art.43428
BibTeX
@article{Brunner2026,
author = {Brunner, Hermine I and Alexeeva, Ekaterina and Bandeira, Marcia and Carrasco, Ruy and Chaitow, Jeffrey and Chiraseveenuprapund, Peter and Ting, Tracy V and Erguven, Muferet and Gottlieb, Beth and Oliveira, Sheila Knupp and Patel, Pooja N and Ozen, Seza and Saad Magalhaes, Claudia and Penadés, Inmaculada Calvo and Gruben, David and Germino, Rebecca and Posner, Holly B and Stockert, Lori and Martini, Alberto and Lovell, Daniel J and Ruperto, Nicolino and Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG)},
title = {Tofacitinib for the Treatment of Juvenile Idiopathic Arthritis: Patient‐Reported Outcomes in a Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Withdrawal Trial},
journal = {Arthritis & Rheumatology},
year = {2026},
doi = {10.1002/art.43428}
}
EUVIMED